Trials / Completed
CompletedNCT01543867
Safety and Efficacy of Long-term Somatropin Treatment in Children
Non-interventional Study of the Safety and Efficacy of Long-term Somatropin Treatment in Children (GrowthWIN II / GrowthWIN II SGA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,442 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The aim of this study is to evaluate safety during the long-term use of somatropin (Norditropin®) in children as well as efficacy on change in height. A subgroup of children small for their gestational age is included.
Conditions
- Growth Hormone Disorder
- Growth Hormone Deficiency in Children
- Foetal Growth Problem
- Small for Gestational Age
- Genetic Disorder
- Turner Syndrome
- Growth Disorder
- Idiopathic Short Stature
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | Prescribed at the discretion of the treating physician according to product labelling |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2012-03-05
- Last updated
- 2015-03-30
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01543867. Inclusion in this directory is not an endorsement.